Webinar Overview

Antibody-drug conjugates (ADCs) have transitioned from a "technology validation phase" into a "scale-up and commercialization phase.” The global ADC market grew from approximately USD 10.4 billion in 2023 to USD 18.5 billion in 2025, with a CAGR exceeding 30%, while next-generation ADCs like bispecific and dual-payload ADCs continue to advance.

As competition extends beyond differentiated molecular design to process robustness, manufacturing capacity and supply chain security, full-cycle CMC capability is becoming a key determinant of successful market entry.

In this webinar, we’ll examine key challenges in scaling ADC processes and explore how advances in conjugation technology address increasingly complex ADCs. Drawing on AsymBio’s hands-on experience, the session will offer both strategic perspectives and practical insights spanning process development through commercial manufacturing.

Key Learning Objectives

-  Identify challenges in scaling ADC manufacturing.

-  Explore conjugation advances for complex ADCs.

-  Understand CMC needs across development, manufacturing, and supply chains.

Speaker Biography

Song Liang

Senior Director, Department of MSAT, AsymBio